newsfilter
← Earnings
Earnings Releases·

Aptevo Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $6.5 million in Q3 2026 from $7.5 million in Q3 2025, while cash and cash equivalents decreased to $8.3 million from $9.8 million at the end of Q2 2026.
  • Financing activities in August 2026 generated approximately $4.1 million in net proceeds, including a private placement of 861,708 shares and warrant exercises totaling $1.0 million.
  • Mipletamig demonstrated a 79% remission rate (CR or CRi) in 14 evaluable TP53-mutated AML patients, with 10 of 47 patients advancing to potentially curative stem cell transplantation.
  • The RAINIER Phase 1b dose optimization study is targeted for completion by year-end 2026, with regulatory interactions planned for the first half of 2027.
  • A strategic collaboration with Niowave is underway to develop up to three radiopharmaceutical oncology programs, while preclinical molecules are expected to advance into IND-enabling studies in 2027.
Company
APTEVO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology